Treatment of Neurogenic Bladder with Elevated Systolic Blood Pressure in Autonomic Dysreflexia (Spinal Cord Injury at T6 or Above)
Autonomic dysreflexia (AD) is a medical emergency that occurs specifically in patients with spinal cord injury at the neurologic level T6 or above. When systolic blood pressure exceeds 150 mm Hg, or rises 20 mm Hg above a patient's baseline, alongside persistent classic symptoms, immediate structured management is required.
This protocol addresses neurogenic bladder in the presence of:
- Autonomic dysreflexia
- Spinal cord injury at neurologic level T6 or above
- Systolic blood pressure >150 mm Hg or >20 mm Hg above baseline
Patients exhibiting persistent classic symptoms — including flushing, sweating, headache, blurry vision, or a sense of impending doom — who remain inadequately managed require escalation of care.
When blood pressure remains critically elevated in this setting, management involves escalating care to an intensively monitored environment for rapid blood pressure control, with alpha-adrenergic blocking agents among the pharmacological options that may be employed — the complete regimen, sequencing, and full set of options are available in the full protocol.
AD is a medical emergency specific to patients with SCI at the neurologic level T6 or above.
Patients with a systolic blood pressure greater than 150 mm Hg and/or 20 mm Hg above baseline who exhibit persistent classic symptoms such as flushing, sweating, headache, blurry vision, and a sense of impending doom are not adequately managed.
If such antihypertensive compounds do not alleviate symptoms, then escalating care to an intensively monitored setting may be appropriate.
Initiating intravenous administration of sodium nitroprusside may be indicated for rapid titration of blood pressure.
Alpha-adrenergic receptor blocking agents (e.g., terazosin, a specific alpha-1 adrenergic antagonist) appear to prevent serious harm from AD.
Another alpha 1-adrenergic antagonist, prazosin (3 mg twice a day, given for 2 weeks), has been reported to reduce both the severity and duration of AD episodes in cervical and high thoracic SCI individuals.
View source ↗